Bayer and its collaboration partner Regeneron presented results from the open-label extension study of the clinical trial PULSAR in patients with neovascular (wet) age-related macular degeneration (nAMD) at… read more.
Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for… read more.
Despite evidence of the risk of malformations at birth, or birth defects, use of some antiseizure drugs during pregnancy has persisted, according to a study published on July… read more.
GSK plc announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial Virus Vaccine,… read more.
Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult… read more.
Researchers report that treatment of type 2 diabetes with glucagon- like peptide- 1 receptor agonists (GLP- 1 RAs) more effectively reduces the subsequent risk of dementia than treatment… read more.
A comprehensive new study analysing data from over 160,000 adults finds that walking approximately 7,000 steps per day is associated with reductions in the risk of several serious… read more.
Incyte announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October… read more.
Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen… read more.
Medical tourism for bariatric and weight reduction surgery needs urgent regulation to protect recipients’ health, especially as the data show that tourist numbers are increasing despite the advent… read more.
Astellas Pharma said that the FDA has accepted for review a revised application for its complement C5 inhibitor Izervay (avacincaptad pegol) that aims to add positive two-year clinical… read more.
Millions worldwide suffer from UV-induced skin damage, photoaging, and skin cancer annually. Current sunscreen efficacy testing relies on minimal erythema dose (MED) and minimal persistent pigment dose (MPPD);… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
